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T cell anergy is a mechanism of peripheral im-
mune tolerance responsible for the inactivation 
of self-reactive T cells. Anergy occurs as a con-
sequence of a partial or suboptimal T cell acti-
vation (1, 2). In vitro, clonal anergy can be 
induced by the engagement of the TCR in the 
absence of costimulation (e.g., CD28) or by 
stimulation with a weak agonist antigen in the 
presence of costimulation (3, 4). The TCR in 
anergic T cells becomes uncoupled from down-
stream  signaling  pathways,  thus  preventing 
proliferation and cytokine expression in response 
to subsequent antigen encounter (5–7).
Engagement of the TCR in the absence of 
costimulation results in the preferential acti-
vation of calcium signaling with only partial 
activation of those pathways that require co-
stimulation (e.g., Ras/MAPK, PKC, and IKK) 
(8, 9). One of the main targets of calcium sig-
naling in T cells is the phosphatase calcineurin. 
Calcineurin is responsible for the dephosphory-
lation and activation of the NFAT transcription 
factors (10). Three of the four calcineurin-reg-
ulated members of the NFAT family are ex-
pressed in T cells: NFAT1 (NFATp, NFATc2), 
NFAT2  (NFATc,  NFATc1),  and  NFAT4 
(NFATc3)  (11,  12).  NFAT  proteins  contain 
three distinct domains: the NFAT homology 
region (NHR), the Rel-homology region (RHR), 
and the C-terminal domain. The NHR is con-
served in all calcium-regulated NFAT proteins 
and contains a strong transactivation domain and 
a regulatory domain, containing several serine-
rich regions and the docking sites for calcineu-
rin and the NFAT kinases (11, 12). The RHR 
is highly conserved within all NFAT proteins 
and shares structural homology with the Rel 
domain of the NF-B family of transcription 
factors. This is the region that binds DNA and 
it is also involved in mediating protein–protein 
interactions with other transcriptional partners 
(11, 12). The RHR of NFAT proteins contains 
two functionally distinct domains, the N-ter-
minal (RHR-N) and the C-terminal (RHR-C). 
The RHR-N makes most of the base-specific 
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In T cells, anergy can be induced after T cell receptor engagement in the absence of 
costimulation. Under these conditions, the expression of a specific set of anergy-associated 
genes is activated. Several lines of evidence suggest that nuclear factor of activated T cells 
(NFAT) proteins may regulate the expression of many of those genes; however, the nature 
of the complexes responsible for the induction of this new program of gene expression is 
unknown. Here, we show that transcriptional complexes formed by NFAT homodimers are 
directly responsible for the activation of at least two anergy-inducing genes, Grail and 
Caspase3. Our data shows that Grail expression is activated by direct binding of NFAT 
dimers to the Grail promoter at two different sites. Consequently, a mutant NFAT protein 
with impaired ability to dimerize is not able to induce an unresponsive state in T cells. Our 
results not only identify a new biological function for NFAT dimers but also reveal the 
different nature of NFAT-containing complexes that induce anergy versus those that are 
activated during a productive immune response. These data also establish a basis for the 
design of immunomodulatory strategies that specifically target each type of complex.
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After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
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we analyzed binding of the NFAT1 RHR to probes contain-
ing two minimal consensus NFAT sites (GGAA) separated by 
1 or 6 nt. As expected, recombinant NFAT1 RHR homodi-
mers formed on the probe with a 1-nt spacer. Incubation of 
this probe with increasing amounts of recombinant NFAT1 
RHR yielded increasing amounts of dimers (Fig. 1 A). How-
ever, dimer formation was almost completely absent when a 
6-nt spacer was inserted between both NFAT monomer sites 
(Fig. 1 B). These data suggested that the binding of two 
NFAT1 RHR molecules to B-like sites might be coopera-
tive, and therefore disruption of the protein–protein contacts 
that maintained both NFAT molecules together should pre-
vent binding of dimers onto the DNA.
Analysis of the crystal structure of the NFAT1 RHR 
dimers (16, 17) allowed us to identify a series of residues 
located in the dimer interface that, when mutated, should 
impair protein–protein interactions (Fig. 1 C). Deletion of 
the  CC  loop  (aa616-623)  in  the  RHR-C  generated  a 
mutant with reduced capacity to form dimers, although 
these could still be detected with high concentrations of 
the CC loop-deleted NFAT1 RHR (Fig. 1 D). Addi-
tional mutations on Q671 and Q673 produced a protein 
with a complete impairment of its ability to bind B-like 
sites as a dimer (Fig. 1 D).
All mutations were performed in residues located in the 
RHR-C and, in theory, should not affect NFAT1’s ability to 
form complexes with Fos and Jun proteins on composite sites 
because these interactions occur predominantly through the 
RHR-N  (Fig.  S1,  available  at  http://www.jem.org/cgi/
content/full/jem.20082731/DC1). To test this hypothesis, 
recombinant RHR was incubated with increasing amounts 
of c-Fos and c-Jun, and a probe containing the ARRE2 
composite site of the murine Il2 promoter (see Supplemental 
materials and methods). Binding reactions showed that the 
mutant lacking the CC loop and bearing Q to A substitutions 
on Q671 and Q673 (CCQQ–AA), had the same ability to 
form cooperative complexes with Fos and Jun as the WT 
RHR (Fig. 1 E).
Next,  we  tested  whether  a  full-length  NFAT1  protein 
bearing those mutations would also show dimer formation im-
pairment. Nuclear extracts prepared from HEK293 cells trans-
fected with plasmids encoding WT NFAT1 or a CCQQ-EE 
mutant were analyzed by EMSA using a probe containing a 
B-like dimer site. Glutamines were substituted for glutamic 
acid in this mutant to introduce electrostatic repulsion between 
monomers. This mutant showed almost no capacity to form 
dimers, but retained its ability to bind DNA and to form com-
plexes with AP-1 (Fig. 1, F–H). Direct targeting of the dimer 
interface can, thus, prevent dimer formation without affecting 
NFAT interactions with AP-1 proteins.
Disruption of NFAT homodimer formation results in lack  
of transcriptional activity from B-like dimer sites
Next, we determined if mutations in the dimer interface 
would inhibit NFAT-induced transcription from a promoter 
containing  B-like  elements.  Jurkat  cells  were  transfected 
DNA contacts and is also involved in interactions with other 
transcription factors (13–18). In resting T cells, NFAT pro-
teins reside in the cytosol in a highly phosphorylated state. 
After antigen encounter, activated calcineurin dephosphory-
lates several serine residues located in the N-terminal regula-
tory domain of NFAT proteins leading to their translocation 
into the nucleus (19). In response to different stimuli and cell 
conditions, the integration of calcium signaling with other 
signaling pathways determines NFAT interactions with dis-
tinct transcriptional partners that result in the activation of 
specific cellular programs. In activated T cells, NFAT coop-
erates with AP-1 transcription factors to form cooperative 
ternary  complexes  at  NFAT–AP-1  composite  sites  that   
induce the expression of activation-induced genes (20, 21). 
NFAT can also synergize with lineage-specific factors (e.g., 
T-bet and GATA3) and contribute to the programs of differ-
entiation that generate Th type 1 or 2 cells (22, 23). Similarly, 
cooperation between NFAT and Foxp3 seems to be essential 
for regulatory T (T reg) cell function and development (24).
In response to tolerizing stimuli, T cells activate a pro-
gram of gene expression that is responsible for the uncou-
pling of the TCR from downstream signaling and for the 
suppression of cytokine expression (25). Anergy-associated 
genes are different from those genes activated during a pro-
ductive immune response, and therefore their expression 
must be regulated by different transcriptional complexes (9, 
26, 27). These genes include, among others, several E3 ubiq-
uitin ligases, such as Cblb, Itch, and Grail; transcription factors, 
such as Egr2, Egr3, and Ikaros; Caspase3; and diacylglycerol 
kinase  (Dgka) (9, 28–35). The expression of many of these 
genes seems to be controlled by NFAT, as their expression 
is drastically reduced in T cells that lack NFAT1 (9). The 
mechanisms that control the regulation and the nature of the 
NFAT-containing  transcriptional  complexes  involved  re-
main largely unknown.
Here, we show that transcriptional complexes formed by 
NFAT dimers regulate the induction of T cell anergy. We 
present evidence that these complexes regulate the expres-
sion of anergy-inducing genes, including Grail and Caspase3. 
We show that, under anergizing conditions, NFAT dimers 
bind to two B-like sites in the proximal Grail promoter and 
directly induce its expression, making NFAT dimer forma-
tion necessary to induce T cell unresponsiveness in vitro and 
in vivo. Our data support a model in which NFAT dimers 
regulate the establishment of anergy in T cells, and suggest 
that it should be possible to independently disrupt the sur-
faces involved in NFAT–NFAT or NFAT–AP-1 interactions 
to modulate the activation or inhibition of T cell responses.
RESULTS
Mutations of critical residues in the RHR-C interfere  
with NFAT homodimerization
The RHR of NFAT1 had been previously shown to have 
the ability to form homodimers on specific DNA sites con-
taining two NFAT core binding sites separated by 1 or 2 nt 
(16, 17). To test the cooperative nature of these complexes, JEM VOL. 206, April 13, 2009 
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necessary to induce transcription from B-like sites, as the 
CCQQ-EE  mutant  showed  almost  no  transcriptional 
activity (Fig. 2 A). All NFAT1 proteins tested were, how-
ever, equally active when a reporter containing three tandem 
ARRE2 sites from the Il2 promoter was used (Fig. 2 B), 
confirming that disruption of the dimer interface did not 
affect NFAT interactions with Fos or Jun.
To exclude that NFAT proteins could bind as monomers 
and activate transcription, the activity of constitutively active 
NFAT1 proteins was measured using a reporter plasmid con-
taining 6 tandem copies of the core “GGAA” NFAT binding 
site. Neither the WT nor the CCQQ-EE mutant proteins 
showed any activity on this vector (Fig. 2 C). A reporter con-
taining 6 9-bp B-like sites was used as control and, as expected, 
only the WT protein could activate its transcription (Fig. 2 C).
with vectors encoding constitutively active forms of WT or 
the CCQQ-EE NFAT1 and a reporter vector containing 
two tandem B-like sites. We have previously shown that 
these active NFAT proteins, which contain several serine-to-
alanine substitutions in key residues located in the regulatory 
region of the NHR domain, are constitutively nuclear and 
insensitive to the inhibitory effect of cyclosporine A (CsA) 
(19). Therefore, to assess the effect of the plasmid-encoded 
NFAT proteins, transfected cells were treated with CsA to 
block endogenous NFAT activation. WT NFAT1 was tran-
scriptionally active on B-like sites. Its transcriptional activity 
was similar in cells treated with or without ionomycin, sug-
gesting that NFAT1 did not require cooperation with other 
calcium-induced transcription factors to activate that pro-
moter (Fig. 2 A). Cooperative dimer formation was clearly 
Figure 1.  Mutations of critical residues in the NFAT1 dimer interface disrupt dimer formation without affecting DNA binding affinity or 
cooperation with AP-1. (A) EMSAs were performed using a probe containing a B-like site and increasing amounts of recombinant NFAT1 RHR. Two 
complexes are identified: NFAT1 monomers (N) and dimers (N–N). Graph shows the relative percentage of dimer complexes compared with the total RHR 
bound to DNA. FP, free probe. (B) EMSAs were performed using recombinant NFAT1 RHR and either a probe containing a consensus B-like site (left) or a 
probe in which the two core NFAT binding sites in a B-like site were separated by 6 nt. (C) Representation of the crystal structure of RHR-C domains in 
the NFAT1 dimer. Residues involved in the dimer interface are highlighted. (D) Binding of recombinant WT NFAT1 RHR or the dimerization mutants CC’ 
and CC’QQ-AA was assayed using a probe containing a B-like dimer site incubated with increasing concentration of these proteins. (E) Increasing 
amounts of recombinant c-Fos and c-Jun proteins were incubated with constant amounts of recombinant WT NFAT1 RHR or the CC’QQ-AA mutant to 
analyze their ability to form ternary complexes on a probe containing a NFAT–AP-1 composite site. N, RHR monomer; N-A, RHR–cFos–cJun complex.  
(F–H). Nuclear extracts prepared from HEK293 cells transfected with plasmids expressing GFP (-), WT NFAT1, or the CC’QQ-EE mutant were analyzed by 
EMSA to determine the ability of these proteins to form dimers (F), using a probe containing a B-like site; to bind DNA (G); and to form complexes with 
AP-1 (H), using a probe containing an NFAT–AP-1 composite site. N-A, NFAT1–cFos–cJun complex. *, unspecific bands.870 NFAT DIMERS REGULATE T CELL ANERGY | Soto-Nieves et al.
were always treated with CsA to block endogenous NFAT 
activation. Whereas the expression of Grg4 and Dgka was also 
up-regulated by the CCQQ-EE mutant, this protein failed 
to induce the expression of Grail or Caspase3 (Fig. 3 A). 
These results indicated that the transcription of some anergy-
inducing genes, such as Grail or Caspase3, was directly or 
indirectly regulated by transcriptional complexes containing 
NFAT dimers. Transcription of other anergy-associated genes, 
such as Grg4 or Dgka, although still dependent on NFAT 
NFAT dimers activate the expression of anergy- 
inducing genes
Having shown that NFAT1 dimers were transcriptionally 
active, we determined whether they would control the tran-
scription of anergy-associated genes in T cells. For that pur-
pose, we transduced primary Th1 cells with retroviruses 
expressing constitutively active forms of WT or CCQQ-
EE NFAT1 proteins and analyzed the expression of four of 
the genes that had previously been suggested to be NFAT 
dependent (9, 30). Confirming previous data, quantitative 
real-time PCR (qPCR) analysis revealed that the expression 
of those genes was up-regulated in Th1 cells in response   
to increases in intracellular calcium caused by ionomycin, 
whereas CsA blocked their expression (Fig. 3 A).
Transcription of those genes was clearly NFAT depen-
dent, as it was induced in cells expressing an active WT 
NFAT1 at similar levels to those detected in ionomycin-
treated cells (Fig. 3 A). As in previous experiments, these cells 
Figure 2.  The NFAT1 CC’QQ-EE mutant cannot transactivate 
from dimer sites, but conserves full activity on NFAT–AP1 compos-
ite sites. Jurkat T cells were cotransfected with reporter plasmids in 
which the expression of the luciferase gene was driven by enhancers con-
taining tandem B-like sites (A), composite NFAT–AP-1 sites (B), or NFAT 
monomer binding sites (C), as well as an empty control vector or plasmids 
expressing an HA-tagged constitutively active NFAT1 (WT) or the CC’QQ-
EE dimerization mutant protein. Cells were then treated with CsA, CsA 
and ionomycin (A and C), or CsA+ionomycin+PMA (B) for 8 h, and lucifer-
ase activity was measured. Normalized values (to the activity of the stim-
ulated cells expressing WT NFAT1) are presented from three to eight 
independent experiments. Error bars are the SEM. (inset) Immunoblot of 
NFAT1 WT and CC’QQ-EE expression in transfected cells using an anti-
HA antibody.
Figure 3.  Expression of the anergy-associated genes Grail and 
Caspase3 is regulated by NFAT1 dimers. (A) Primary mouse Th1 cells 
were transduced with retroviral RV-IRES-GFP empty vector (GFP) or retro-
viruses expressing the constitutively active WT NFAT1 (WT) or the 
CC’QQ-EE mutant. Cells were sorted for GFP expression (infected cells) 
and left resting or treated with ionomycin or CsA+ionomycin for 4 h. RNA 
was prepared, and the expression of four anergy-associated genes was 
quantified by qPCR. Values are normalized to control untreated Th1 cells. 
The data represents the mean of seven independent experiments ± SEM.  
*, P < 0.05. (B) Primary Nfat1+/+ or Nfat1/ CD4+ T cells were transfected 
with plasmids expressing WT NFAT1 or the CC’QQ-EE mutant and an Il2 
promoter–luciferase reporter vector. 24 h after transfection, cells were 
left resting or activated with PMA and ionomycin for 8 h. Luciferase  
activity (mean + SEM) from three independent experiments is shown.  
(C) Th1 cells from Nfat1+/+ or Nfat1/ mice were stimulated with 1 µm 
ionomycin for 6 h. RNA was obtained, and expression of Grail and Cas-
pase3 was measured by qPCR. Values (mean + SEM) show fold induction 
of the expression of those genes compared with the untreated cells from 
three independent experiments. (D) NIH-3T3 cells were transfected with 
plasmids expressing NFAT1 (N1), NFAT2 (N2), or NFAT4 (N4), and reporter 
plasmids in which the expression of luciferase was controlled by the Grail 
promoter (pGrail) or by enhancers containing three tandem copies of the 
ARRE2 site of the Il2 promoter. Luciferase values are the mean + SEM of 
three different experiments.JEM VOL. 206, April 13, 2009 
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To determine if NFAT-dimers would bind directly to 
the Grail promoter and regulate its expression, we followed 
two different approaches. First, we assessed the recruitment 
of NFAT1 to the Grail promoter by chromatin immunopre-
cipitation. We used an anti-NFAT1 antibody to pull down 
proteins, would be activated by other NFAT-containing tran-
scriptional complexes. To confirm that the CCQQ-EE 
mutant was still active on promoters containing nondimer 
sites, primary Nfat1+/+ or Nfat1/ Th1 cells were cotrans-
fected with plasmids expressing WT or CCQQ-EE NFAT1 
proteins and a reporter vector in which the expression of lu-
ciferase was regulated by the murine proximal Il2 promoter. 
In these assays, the CCQQ-EE mutant showed similar trans-
activational activity as the WT NFAT1 protein (Fig. 3 B).
Given that we had previously shown that Nfat1/ T 
cells were less susceptible to anergizing stimuli and showed 
a markedly reduced ability to up-regulate the expression of 
most anergy-associated genes, we focused our study on the 
role that this NFAT protein had on the regulation of the ex-
pression of those genes. To determine if other NFAT pro-
teins might also form dimers and be able to compensate for 
the lack of NFAT1, we analyzed the induction of the expres-
sion of Grail and Caspase3 in Nfat1+/+ and Nfta1/ T cells. 
Our results showed that T cells that lacked NFAT1 were not 
able to up-regulate the expression of these dimer-dependent 
genes in response to calcium signaling (Fig. 3 C). To further 
study if, in any other circumstances, dimers containing other 
NFAT family members could activate the expression of those 
genes, we cotransfected NIH3T3 cells, which express very 
low levels of endogenous NFAT proteins, with plasmids ex-
pressing NFAT1, NFAT2, or NFAT4 (the three NFAT pro-
teins that can be found in T cells) and a reporter vector in 
which the promoter of Grail directed the expression of lucif-
erase. As expected, NFAT1 induced transcription from the 
Grail promoter (Fig. 3 D). Similar results were obtained for 
NFAT4, but NFAT2 did not show any transactivational ac-
tivity on the Grail promoter, even though it was perfectly ca-
pable of inducing the expression of a reporter controlled by 
the Il2 promoter ARRE2 site, which contains composite 
NFAT–AP-1 sites (Fig. 3 D).
NFAT1 induces Grail expression by binding to B-like sites 
located in the Grail promoter
To determine whether the expression of Grail and Caspase3 
could be induced by the NFAT dimer-mediated activation of 
their promoters, we measured the capacity of WT NFAT1 and 
the CCQQ-EE dimerization mutant to activate two re-
porter vectors where the expression of the luciferase gene was 
controlled by those promoters. We did not detect any NFAT-
mediated activation of the Caspase3 proximal promoter (un-
published  data).  However,  expression  of  an  active  form  of 
NFAT1 was able to activate the Grail promoter (Fig. 4 A). 
Levels of activation were almost identical in cells treated with 
CsA and in cells treated with CsA and ionomycin, which sug-
gested that, under the conditions used in the assay, NFAT did 
not require additional calcium-activated proteins to transacti-
vate the Grail promoter (Fig. 4 A). Supporting the results ob-
tained in primary Th1 cells, the CCQQ-EE dimerization 
mutant NFAT1 protein had a markedly reduced ability to acti-
vate transcription from the Grail promoter (Fig. 4 A), confirm-
ing that Grail expression was dependent on NFAT dimers.
Figure 4.  NFAT1 dimers activate the transcription of Grail by 
binding two b-like sites in the Grail promoter. (A) Jurkat T cells were 
cotransfected with a luciferase reporter vector containing the Grail pro-
moter (89 to 880), and a control empty plasmid or increasing concen-
tration of plasmids expressing a constitutively active WT NFAT1 or the 
CC’QQ-EE mutant. 36 h after transfection, cells were treated with CsA or 
CsA+ionomycin for 8 h, and luciferase activity was measured. Values are 
normalized to luciferase levels of activated cells transfected with the con-
trol empty vector. Graph shows the mean of three independent experi-
ments ± SEM. (B) Primary mouse Th1 cells were treated with ionomycin 
(iono) or PMA+ionomycin for 3 h. ChIP was performed using an anti-
NFAT1 antibody. NFAT binding to DNA was quantified by qPCR analysis 
using primers for the proximal regions of the Il2 promoter (left) and the 
Grail promoter (right). Bars show the mean + SEM of values for fold in-
duction (relative to resting cells) from three independent experiments.  
(C) Jurkat T cells were transiently cotransfected with a luciferase reporter 
vector containing the Grail promoter with or without mutations in the 
NFAT dimer sites located at positions 355 or 455, and a control empty 
plasmid or a plasmid expressing the constitutively active NFAT1. 36 h 
after transfection, cells were treated with CsA/ionomycin for 8 h and 
luciferase activity was measured. The graph shows the mean of three 
independent experiments + SEM.872 NFAT DIMERS REGULATE T CELL ANERGY | Soto-Nieves et al.
NFAT–DNA complexes in murine Th1 cells, and we quan-
tified binding of NFAT1 by qPCR using specific primers 
for the proximal promoters of the Il2 and Grail genes (see 
Supplemental materials and methods). As expected, NFAT1 
bound the Il2 promoter. Although some binding was already 
detected in cells treated with ionomycin, it was in fully acti-
vated T cells where NFAT1 binding to the Il2 promoter was 
clearly induced (Fig. 4 B). These results were consistent with 
the binding of NFAT–AP-1 complexes to composite sites on 
the Il2 promoter in activated T cells. NFAT1 was also able to 
bind to the Grail promoter; however, the pattern of binding 
was different from the one detected on the Il2 promoter. 
Consistent with the role of NFAT1 in the transcription of 
anergy-inducing genes, NFAT1 bound the Grail promoter 
preferentially in cells receiving an anergizing stimulus (iono-
mycin), whereas full activation of T cells with PMA and ion-
omycin reduced NFAT1 binding (Fig. 4 B).
To determine if two putative dimer sites we had identi-
fied in the Grail promoter (355 gtaacgtttcc and 411 
ggattcttcc) were binding sites for NFAT, and to simultane-
ously measure their contribution to the regulation of Grail 
expression, reporter vectors containing the Grail promoter 
with mutations that disrupted those sites were constructed 
(see Supplemental materials and methods). Analysis of Jur-
kat cells transiently transfected with these plasmids showed 
that disruption of any of those two sites resulted in an   
almost complete loss of NFAT-dependent transcriptional 
activity (Fig. 4 C).
The CCQQ-EE dimerization mutant has an impaired 
ability to induce unresponsiveness in T cells
Expression of an active form of NFAT1 is able to induce un-
responsiveness in T cells (9). To determine the contribution 
of NFAT dimer complexes to the induction of the anergic 
phenotype, we transduced murine Th1 cells with retroviral 
vectors expressing a constitutively active WT NFAT1 or the 
CCQQ-EE mutant and analyzed the ability of these pro-
teins to induce unresponsiveness. Western blot analysis dem-
onstrated that equivalent amounts of both proteins were 
expressed in the sorted infected Th1 cells (Fig. 5 A). As pre-
viously reported (9), Th1 cells transduced with a constitu-
tively active NFAT1 became resistant to stimulation, and 
Figure 5.  Disruption of NFAT1 dimerization ability compromises 
its capacity to induce unresponsiveness in T cells. (A) Primary mouse 
Th1 cells were infected with retrovirus expressing an active form of WT 
NFAT1 (WT) or the CC’QQ-EE mutant. Infected cells were sorted and 
stimulated with anti-CD3 and anti-CD28 for 8 h. IL-2 production was 
quantified by ELISA. The mean + SEM of seven experiments is presented 
(left). *, P < 0.05. (inset) Immunoblot showing protein expression using an 
anti-HA antibody. Fold reduction of IL-2 expression compared with con-
trol infected T cells (anergy index) is also shown (right). (B) Nfat1/ Th1 
cells were transduced with the retroviral RV-IRES-GFP vector or retrovirus 
expressing a WT NFAT1 or the CC’QQ-EE mutant. GFP+ cells were sorted 
and left resting (open bars) or anergized with 1 µm ionomycin (filled 
bars). Cells were then washed, rested for 4 h, and stimulated with plate-
bound anti-CD3 and anti-CD28 for 24 h. IL-2 expression was then mea-
sured by ELISA. Values are the mean + SEM of three independent 
experiments. Uninfected Nfat1+/+ Th1 cells were used as controls. *, P < 
0.05. Fold reduction of IL-2 expression in anergic T cells (anergy index) 
compared with control untreated nonanergic cells is also shown (right). 
(C) CD4+ T cells from DO11.10 mice were transduced with retroviral vec-
tors expressing GFP or GFP and a WT constitutively active NFAT1 or the 
CC’QQ-EE dimerization mutant, sorted for GFP expression and trans-
ferred into BALB/c recipients. Host mice were then challenged subcutane-
ously with CFA or CFA plus OVA323-339 peptide. 7 d after challenge, cells 
were collected from draining lymph nodes and the presence of GFP+CD4+ 
T cells was determined by FACS. A representative experiment is shown. 
Graph shows the mean + SEM of the numbers of GFP+ cells from 4 inde-
pendent experiments. *, P < 0.05.
 JEM VOL. 206, April 13, 2009 
ARTICLE
873
induces a state of unresponsiveness and up-regulates many 
anergy-associated genes (9).
In activated T cells, NFAT cooperates with other tran-
scription factors on multiple cytokine promoters (21, 40). 
However, during anergy induction, many of the NFAT tran-
scription partners, such as AP-1, are not fully activated. Thus, 
other NFAT-containing transcriptional complexes must reg-
ulate the expression of anergy-associated genes. Recently, 
two groups characterized the dimer structure of the NFAT1 
RHR bound to the B-like sites of the human IL-8 pro-
moter and the HIV-1 LTR (16, 17). Our results show that 
NFAT dimers are able to induce transcription from B-like 
sites and regulate the expression of at least two genes respon-
sible for blocking TCR signaling in anergic T cells. Whereas 
NFAT1 can induce the expression of Grail and Caspase3, a 
mutant NFAT1 protein unable to form dimers fails to trans-
activate those two genes. Transient reporter assays indicate 
that the NFAT-dependent regulation of Caspase3 expression 
does not occur through its proximal promoter. It is possible, 
though, that distal control elements containing NFAT sites 
are responsible for the regulation of the expression of this 
gene, as it has been described for several cytokines (41–43). 
Grail, however, is regulated by direct binding of NFAT di-
mers to at least two B-like sites located in its promoter. 
Grail is also posttranslationally regulated by two isoforms of 
the ubiquitin-specific protease Otubain 1 (44). After T cell 
activation, Otubain1 binds Grail and inhibits its deubiqui-
tination, leading to Grail degradation. During anergy induc-
tion, a different spliced form, Otubain1-ARF, is expressed 
and binds and stabilizes Grail by recruitment of USP8 (44). 
It is still unknown how the expression of these isoforms of 
Otubain is regulated, and it would be interesting to deter-
mine if NFAT might also be involved.
Our data indicates that NFAT homodimers are coopera-
tive. Increasing the distance between the NFAT binding hemi-
sites in a B-like site abrogates binding of NFAT dimers. 
Similarly, mutations of the NFAT1 dimer interface that inhibit 
protein–protein interactions result in a markedly reduced abil-
ity of NFAT1 to bind and transactivate from B-like sites. 
Most of the interactions between NFAT and DNA or AP-1 
occur through the RHR-N (Fig. S1) (15), which explains why 
mutations in the RHR-C do not affect the formation of 
NFAT–AP-1 complexes. NFAT-containing transcriptional 
complexes activated during a productive immune response are 
different from those formed during the induction of T cell tol-
erance, and involve different protein surfaces on NFAT. Mol-
ecules could thus be designed to specifically manipulate these 
cellular responses. For instance, targeting the critical residues 
needed for NFAT–AP-1 interactions should interfere with the 
formation of these complexes without affecting dimer forma-
tion, thus skewing T cell responses toward tolerance. Con-
versely, targeting the dimer interface should not affect AP-1 
interactions, and should selectively disrupt dimer transcrip-
tional complexes, tilting T cell responses toward activation.
The NFAT1 residues involved in the dimer interface are 
conserved in NFAT2 and NFAT4 (16, 17). Thus, structurally, 
activation-induced IL-2 expression decreased almost 12-fold 
when compared with control cells. However, the expression 
of the NFAT1 dimerization mutant, although still able to 
cause some inhibition of IL-2 expression, was much less effi-
cient than the WT protein in blocking T cell responses to 
stimulation (3.5-fold compared to 11.8-fold; Fig. 5 A). Simi-
lar results were obtained when Nfat1/ T cells were trans-
duced with retrovirus expressing nonconstitutively active forms 
of NFAT1 or the CCQQ-EE dimerization mutant. As 
previously shown (9), Nfat1/ cells were less susceptible to 
anergizing stimuli than Nfat1+/+ T cells (Fig. 5 B). Restoring 
the expression of NFAT1 by retroviral infection in these 
cells also restored their ability to become anergic in response 
to ionomycin; however, no effect could be detected when 
cells were transduced with a retrovirus that expressed the 
CCQQ-EE mutant protein (Fig. 5 B).
To confirm these results in vivo, adoptive transfer experi-
ments were performed. CD4+ T cells isolated from DO11.10 
mice were adoptively transferred to BALB/c recipients and 
challenged with CFA or OVA323-339 peptide in CFA. Upon 
analysis of the draining lymph nodes 7 d after challenge, pro-
liferative responses could be observed only in mice challenged   
with the antigenic peptide (Fig. S2, available at http://www 
.jem.org/cgi/content/full/jem.20082731/DC1). When trans-
duced T cells expressing GFP alone or GFP and constitutively 
active forms of WT NFAT1 or the CCQQ-EE mutant 
were transferred to BALB/c recipients, increased numbers of 
GFP+ T cells in response to OVA323-339 challenge could be 
readily detected in control GFP-expressing cells, but they were 
almost completely absent in mice receiving cells expressing 
an active WT NFAT1 protein. When cells that expressed the 
CCQQ-EE dimerization mutant NFAT1 protein were 
transferred, it was evident that this protein had lost most of its 
ability to induce unresponsiveness in T cells and clear prolif-
erative responses induced by OVA323-339 challenge could be 
detected in those mice (Fig. 5 C).
DISCUSSION
Tolerizing stimuli induce the expression of a specific set   
of genes that are different from those expressed during a 
productive immune response (9, 27). In various models of 
immune tolerance, an elevation of intracellular Ca2+ can be 
consistently detected (8, 36, 37). In T cells, weakly agonistic 
antigens that induce T cell anergy also elicit sustained in-
creases in the levels of cytoplasmic Ca2+ (8). Thus, tolerizing 
stimuli that cause suboptimal activation of T cells may only 
induce low levels of sustained increase in intracellular Ca2+ 
that have been shown to be sufficient to activate NFAT, but 
not AP-1 or NF-B, proteins (38, 39). Several lines of evi-
dence support the involvement of Ca2+ and NFAT in the 
expression of anergy-associated genes: cells treated with a 
Ca2+ ionophore become unresponsive and up-regulate the 
expression of anergy-associated genes, which can be blocked 
by the calcineurin inhibitor CsA; T cells from Nfat1/ mice 
are hyperactive and more resistant to becoming anergic; and, 
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dence indicates that NFAT–Foxp3 complexes are crucial for 
the development of T reg cell suppressor function (24). How-
ever, we cannot rule out that NFAT dimers might also be 
involved in the regulation of the program of gene expression 
that leads to the establishment of a regulatory phenotype.
The identification of the transcriptional complexes that 
activate distinct programs of gene expression in T cells should 
allow us to understand the mechanisms that regulate specific 
cellular responses. At the same time, this information should 
provide valuable insight to design tools that may interfere 
with the formation or functioning of these complexes, and 
therefore may modulate T cell function.
MATERIALS AND METHODS
Mice. WT or Nfat1/ C57BL6/J, BALB/c, and DO11.10 mice were 
maintained in pathogen-free conditions. All animal work was approved by 
the Animal Institute Committee of the Albert Einstein College of Medicine.
Cell culture. Primary CD4+ T cells were isolated from lymph nodes and 
spleen of 4–6-wk-old mice using anti-CD4–coupled magnetic beads, stimu-
lated with 0.5 µg/ml plate-bound anti-CD3 and anti-CD28, and differenti-
ated for 7 d in the presence of 10 ng/ml IL-12, 10 µg/ml anti–IL-4, and 10 
U/ml of recombinant hIL-2. Cells were cultured in DME supplemented 
with 10% fetal calf serum, 2 mM l-glutamine, nonessential amino acids, and 
essential vitamins, 550 nM l-arginine, 240 nM l-asparagine, 14 nM folic 
acid, and 50 µM -mercaptoethanol. Jurkat, HEK293, and NIH-3T3 cells 
were cultured in DME supplemented with 10% fetal calf serum and 2 mM 
l-glutamine.
Transfections and reporter assays. Jurkat cells were transfected by elec-
troporation in serum-free medium, and murine T cells were transfected by 
electroporation using a Nucleofector electroporator (Amaxa) following the 
manufacturer’s recommendations. 24 h after transfection, cells were stimu-
lated with 1 µM ionomycin and/or 20 nM PMA in the presence or absence 
of 1 µM CsA. 8 h after stimulation, cells were lysed and assayed for luciferase 
activity using the Promega Dual-Luciferase Reporter Assay System. HEK293 
and NIH-3T3 cells were transfected using PolyFect transfection reagent 
(QIAGEN) following the manufacturer’s recommendations.
Retroviral infection of primary T cells. The retroviral vectors RV-
IRES-GFP and RV-CA-HA-NFAT1-IRES-GFP have been previously 
described (9). Phoenix Ecotropic cells (a gift from G. Nolan, Stanford 
University, Palo Alto, CA) were transfected with retroviral vectors. Super-
natants were collected 48 h after transfection, supplemented with 8 µg/ml 
polybrene, and used to infect CD4+ T cells 24 h after stimulation. Infected 
cells were sorted for GFP expression. NFAT expression was assessed by 
immunoblot using an anti-HA antibody.
PCR site-directed mutagenesis. The QuickChange Site-Directed Muta-
genesis kit (Stratagene) was used to remove the CC loop and substitute 
Q671 and Q673 for A or E in the NFAT dimer interface. The two NFAT 
dimer sites at position 355 and 411 on the Grail promoter were mutated 
from GTAACGTTTCC to GTCTCGTAACC and from GGATTCTTCC 
to TAATTCAACC, respectively.
Electrophoretic mobility shift assays (EMSAs). Recombinant proteins 
were expressed fused to hexahistidine tags and purified using Ni-NTA aga-
rose. Nuclear extracts were prepared from transfected HEK293 cells, and 
equal amounts of recombinant or HEK293-expressed NFAT proteins were 
incubated with [32P]-labeled probes containing B-like dimer sites with dif-
ferent 1-, 2-, or 6-bp spacers or a composite NFAT–AP-1 site in a buffer 
containing 10 mM Hepes, pH 7.0, 125 mM NaCl, 10% glycerol, 0.25 mM 
DTT, 100 ng/µl of poly dI-dC, 0.8 mg/µl of BSA for 30 min, and then re-
solved in 4% polyacrylamide gels.
it is likely that other NFAT proteins can also homodimerize 
or even heterodimerize. It has been well characterized that 
redundancy within the NFAT family exists. In general, knock-
ing out one NFAT protein results only in a mild phenotype, 
whereas knocking out two or more members leads to striking 
defects (45–53). The phenotypes of these mice seem to indi-
cate that although NFAT1 and NFAT2 proteins regulate the 
expression  of  activation-induced  genes,  it  is  NFAT1  and 
NFAT4 that might be specifically involved in controlling 
cellular programs that lead to the negative regulation of T cell 
responses. As suggested by the phenotypes of those mice, 
NFAT1 and NFAT4 had a much higher activity on the pro-
moter of Grail than NFAT2. NFAT4 dimers are unlikely to 
compensate for NFAT1, as T cells that lack NFAT1 showed 
an almost complete lack of up-regulation of Grail and Cas-
pase3 when anergized. Although we cannot rule out a possi-
ble role for NFAT1–NFAT4 heterodimers, recent reports 
have indicated that, because of differences in the residues in-
volved in dimer interaction between NFAT1 and NFAT4, 
these complexes are not likely to occur (16).
We  have  also  observed  that  the  regulation  of  other   
anergy-inducing genes, such as Grg4 and Dgka, is NFAT 
dependent but dimer independent. How are these genes 
regulated? Is it possible that NFAT monomers may drive 
their expression? The crystal structure of the NFAT1 RHR 
bound to a single NFAT cognate DNA site shows the forma-
tion of four different DNA–NFAT binary complexes (18). In 
all four, the RHR-N recognizes the DNA and provides a 
relatively rigid domain to interact with other transcriptional 
factors. A flexible linker exists between the RHR-N and 
RHR-C that permits the RHR-C to acquire different con-
formational changes, providing a dynamic surface for pro-
tein–protein interactions. This flexibility should facilitate the 
formation of higher order NFAT transcriptional complexes. 
Our experimental data supports this conclusion and shows 
that NFAT1 is not able to induce any significant transcrip-
tional activity in a reporter vector driven by NFAT monomer 
sites. Overall, the data suggests that NFAT1 must cooperate 
with other transcription factors to activate gene expression. It 
is also possible that NFAT may indirectly regulate the expres-
sion of some anergy-inducing genes. It has recently been 
shown that anergic T cells up-regulate transcription of Cblb 
by inducing the expression of the transcription factors Egr2 
and Egr3 in a NFAT-dependent way (28).
Could NFAT dimers be involved in other cellular func-
tions as well? T reg cells are also intrinsically anergic; they do 
not produce IL-2 and proliferate poorly upon stimulation in 
vitro. A hallmark of T reg cells is the expression of the Foxp3 
transcription factor, which seems to be necessary for T reg 
cell development and suppressor activity (54–56). Recently, 
it has been reported that T reg cells express up to 10 times 
more Grail than naive CD4+ T cells. Grail may thus be nec-
essary to maintain the anergic status of T reg cells and to ac-
quire suppressor activity, as T cells overexpressing Grail gain 
suppressor capacity (57). The mechanism of action and the 
regulation of Grail in T reg cells are unknown. Recent evi-JEM VOL. 206, April 13, 2009 
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Ionomycin-induced anergy. Th1 cells were treated with 1 µM ionomy-
cin for 16 h. In some experiments, CsA at 1 µM was also added 30 min be-
fore the ionomycin treatment. Cells were then washed and rested for 2–4 h 
in fresh medium before stimulation.
ELISA. 25–50 × 103 Th1 cells were stimulated with 0.5 µg/ml plate-bound 
anti-CD3 and anti-CD28 in 96-well plates. Supernatants were collected 8 h 
after stimulation, and IL-2 levels were measured in a sandwich ELISA.
qPCR. Total RNA samples were prepared from sorted GFP+ retrovirally 
transduced mouse Th1 cells. cDNA was synthesized using Superscript II re-
verse transcription. Gene expression was analyzed using SYBR Green in a 
Smart Cycler II thermocycler. A threshold was set in the linear range of the 
amplification  curve  (fluorescence  =  f[cycle]),  and  the  number  of  cycles 
needed to reach it was calculated for every sample. Expression of each gene 
was normalized to levels of actin, and the fold induction was calculated rela-
tive to the resting values.
Chromatin immunoprecipitation (ChIP) assays. NFAT1 binding was 
assayed using a ChIP assay kit (Millipore). Nuclear lysates from 107 Th1 cells 
untreated or treated with 1 µM ionomycin or 1 µM ionomycin/20 nM 
PMA for 2 h were subjected to immunoprecipitation overnight at 4°C with 
an anti-NFAT1 antibody (ABR). Taqman probes were used to analyze the 
ChIP products by qPCR. Results were expressed as fold induction over val-
ues in resting cells and were normalized by input values.
Adoptive transfers. 5 × 105 retrovirally transduced, GFP+ DO11.10 T 
cells were transferred into BALB/c recipients by tail vein injection. 1 d after 
the transfer, mice received a subcutaneous injection of 200 µl of complete 
Freund’s adjuvant in the presence or absence of 400 µg of OVA323-339 pep-
tide. On day 7, draining lymph nodes were collected. Cell suspensions were 
prepared and labeled with a PE-coupled anti-CD4 antibody, and the num-
ber of CD4+GFP+ T cells was measured by FACS.
Statistical analysis. Differences in the inhibition of IL-2 production and 
gene expression in anergic T cells were analyzed using a Student’s t test.
Online supplemental material. Fig. S1 shows an amino acid sequences 
comparison of the of the RHRs of NFAT1, 2, and 4, highlighting the resi-
dues involved in contacts with Fos and Jun, those involved in NFAT-NFAT 
dimer interactions, and the amino acids mutated in this study. Fig. S2 shows 
the proliferative responses of adoptively transferred DO11.10 TCR trans-
genic T cells in BALB/c mice in response to stimulation with OVA323-339 
peptide. The Supplemental materials and methods describes the sequences of 
the DNA probes and primers used in this study. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20082731/DC1.
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